📊 KTTAW Key Takeaways
Is KTTAW a Good Investment? Thesis Analysis
Pasithea is an early-stage biotech with minimal revenue (486.6K) and severe operating losses (-20.9M), indicating pre-commercial development stage. Despite maintaining adequate liquidity with $55.2M cash and no debt, the company faces a critical runway constraint with annual cash burn of $15-20M, providing only 2-3 years of operational runway without achieving revenue inflection or securing additional capital.
Why Buy KTTAW? Key Strengths
- Strong balance sheet with $55.2M cash and zero debt, providing cushion for R&D operations
- Excellent short-term liquidity (11.35x current ratio) supports continued clinical development spending
- 27% gross margin on existing revenue suggests potential unit economics if commercialization is achieved
KTTAW Investment Risks to Consider
- Catastrophic operating losses with -4286.7% operating margin; negative cash flow of -15.2M annually unsustainable without external funding
- Minimal revenue base (486.6K) with unclear path to profitability; 3130% revenue growth on near-zero base provides little evidence of commercial viability
- Limited cash runway of 2-3 years at current burn rate necessitates dilutive capital raises or major clinical/commercial breakthrough
- Increasing net losses (-20.4M with worsening 46.9% YoY trend) while EPS marginally improves suggests significant shareholder dilution masking deteriorating fundamentals
- Zero insider Form 4 activity in 90 days may indicate limited management confidence or activity
Key Metrics to Watch
- Quarterly revenue sustainability and whether 3130% growth continues or reverts
- Operating cash burn trajectory relative to clinical trial milestones and development stage progression
- Subsequent capital raise size and dilution impact on existing shareholders
- Drug candidate advancement milestones and regulatory approval progress
KTTAW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 11.35x current ratio provides a solid financial cushion.
KTTAW Profitability Ratios
KTTAW vs Healthcare Sector
How Pasithea Therapeutics Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KTTAW Overvalued or Undervalued?
Based on fundamental analysis, Pasithea Therapeutics Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KTTAW Balance Sheet & Liquidity
KTTAW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Pasithea Therapeutics Corp.'s revenue has grown significantly by 3,130% over the 5-year period, indicating strong business expansion. The most recent EPS of $-12.69 indicates the company is currently unprofitable.
KTTAW Growth Metrics (YoY)
KTTAW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | $13.7K | -$1.3M | $-0.01 |
| Q3 2022 | $218.6K | -$549.6K | $-0.17 |
| Q2 2022 | $13.6K | -$549.6K | $-0.09 |
| Q1 2022 | $13.7K | -$549.6K | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KTTAW Capital Allocation
KTTAW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Pasithea Therapeutics Corp. (CIK: 0001841330)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KTTAW
What is the AI rating for KTTAW?
Pasithea Therapeutics Corp. (KTTAW) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KTTAW's key strengths?
Claude: Strong balance sheet with $55.2M cash and zero debt, providing cushion for R&D operations. Excellent short-term liquidity (11.35x current ratio) supports continued clinical development spending.
What are the risks of investing in KTTAW?
Claude: Catastrophic operating losses with -4286.7% operating margin; negative cash flow of -15.2M annually unsustainable without external funding. Minimal revenue base (486.6K) with unclear path to profitability; 3130% revenue growth on near-zero base provides little evidence of commercial viability.
What is KTTAW's revenue and growth?
Pasithea Therapeutics Corp. reported revenue of $486.6K.
Does KTTAW pay dividends?
Pasithea Therapeutics Corp. does not currently pay dividends.
Where can I find KTTAW SEC filings?
Official SEC filings for Pasithea Therapeutics Corp. (CIK: 0001841330) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KTTAW's EPS?
Pasithea Therapeutics Corp. has a diluted EPS of $-2.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KTTAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pasithea Therapeutics Corp. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KTTAW stock overvalued or undervalued?
Valuation metrics for KTTAW: ROE of -37.0% (sector avg: 15%), net margin of -4,198.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KTTAW stock in 2026?
Our dual AI analysis gives Pasithea Therapeutics Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KTTAW's free cash flow?
Pasithea Therapeutics Corp.'s operating cash flow is $-15.2M, with capital expenditures of $34.3K. FCF margin is -3,133.4%.
How does KTTAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,198.4% (avg: 12%), ROE -37.0% (avg: 15%), current ratio 11.35 (avg: 2).